JP2024513391A5 - - Google Patents

Info

Publication number
JP2024513391A5
JP2024513391A5 JP2023560496A JP2023560496A JP2024513391A5 JP 2024513391 A5 JP2024513391 A5 JP 2024513391A5 JP 2023560496 A JP2023560496 A JP 2023560496A JP 2023560496 A JP2023560496 A JP 2023560496A JP 2024513391 A5 JP2024513391 A5 JP 2024513391A5
Authority
JP
Japan
Application number
JP2023560496A
Other languages
Japanese (ja)
Other versions
JP7849383B2 (ja
JP2024513391A (ja
JPWO2022212700A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/022817 external-priority patent/WO2022212700A2/en
Publication of JP2024513391A publication Critical patent/JP2024513391A/ja
Publication of JP2024513391A5 publication Critical patent/JP2024513391A5/ja
Publication of JPWO2022212700A5 publication Critical patent/JPWO2022212700A5/ja
Application granted granted Critical
Publication of JP7849383B2 publication Critical patent/JP7849383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023560496A 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物 Active JP7849383B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169545P 2021-04-01 2021-04-01
US63/169,545 2021-04-01
US202263325328P 2022-03-30 2022-03-30
US63/325,328 2022-03-30
PCT/US2022/022817 WO2022212700A2 (en) 2021-04-01 2022-03-31 Conjugated hepcidin mimetics

Publications (4)

Publication Number Publication Date
JP2024513391A JP2024513391A (ja) 2024-03-25
JP2024513391A5 true JP2024513391A5 (https=) 2025-03-06
JPWO2022212700A5 JPWO2022212700A5 (https=) 2025-03-06
JP7849383B2 JP7849383B2 (ja) 2026-04-21

Family

ID=83459967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560496A Active JP7849383B2 (ja) 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物

Country Status (7)

Country Link
US (1) US20240209053A1 (https=)
EP (1) EP4314014A4 (https=)
JP (1) JP7849383B2 (https=)
AU (1) AU2022249097A1 (https=)
CA (1) CA3214153A1 (https=)
TW (1) TW202304952A (https=)
WO (1) WO2022212700A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040152868A1 (en) * 2001-03-30 2004-08-05 Larsen Bjarne Due Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
WO2007093013A1 (en) 2006-02-17 2007-08-23 Monash University Methods for the synthesis of dicarba bridges in organic compounds
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
US9624268B2 (en) * 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US20190002503A1 (en) * 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3749345A4 (en) * 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS

Similar Documents

Publication Publication Date Title
JP2024513391A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13151U (https=)
BY13160U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
BY13149U (https=)
BY13150U (https=)
BY13135U (https=)